Cargando…
Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal
Background: this study was designed to compare the long-term survival outcomes of patients prepared for radioiodine (RAI) therapy using either thyroid hormone withdrawal (THW) or recombinant human thyrotropin (rhTSH) stimulation, by specifically focusing on cases with distant metastases from papilla...
Autores principales: | Tsai, Hsi-Chen, Ho, Kung-Chu, Chen, Shih-Hsin, Tseng, Jing-Ren, Yang, Lan-Yan, Lin, Kun-Ju, Cheng, Ju-Chin, Liou, Miaw-Jene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775305/ https://www.ncbi.nlm.nih.gov/pubmed/35054388 http://dx.doi.org/10.3390/diagnostics12010221 |
Ejemplares similares
-
MON-LB87 Recombinant Human TSH vs Thyroid Hormone Withdrawal Preparation for Radioiodine Ablation in Pediatric Differentiated Thyroid Cancer
por: Schumm, Max A, et al.
Publicado: (2020) -
Five-Year Survival Is Similar in Thyroid Cancer Patients with Distant Metastases Prepared for Radioactive Iodine Therapy with either Thyroid Hormone Withdrawal or Recombinant Human TSH
por: Tala, H., et al.
Publicado: (2011) -
Circulating epithelial cell counts for monitoring the therapeutic outcome of patients with papillary thyroid carcinoma
por: Tseng, Ching-Ping, et al.
Publicado: (2017) -
Radioiodine therapy under rhTSH for follicular thyroid carcinoma with sellar metastasis and non-rising TSH
por: Taywade, Sameer Kamalakar, et al.
Publicado: (2016) -
SAT510 I-131 Therapy with Dosimetry for Advanced Thyroid Carcinoma: Recombinant TSH vs Thyroid Hormone Withdrawal
por: Awad, Dana, et al.
Publicado: (2023)